Novel therapies in pediatric rheumatic diseases

[Guest guest]

Novel therapies in pediatric rheumatic diseases

Current Opinion in Pediatrics: Volume 15(6) December 2003 pp 579-585

http://www.co-pediatrics.com/

Abstract

Purpose of review: Better understanding of the etiology of autoimmune

diseases and their progression has brought about numerous novel

therapies used in the treatment of pediatric rheumatic diseases. The

introduction of biologic agents such as tumor necrosis factor inhibitors

has changed how we approach and manage autoimmune diseases. This has led

to a proliferation of other therapies targeting specific inflammatory

processes evident in many rheumatic illnesses, with hopes of improving

efficacy and decreasing adverse effects from treatment.

Recent findings: Clinical studies demonstrate safety and efficacy of

these newer medications in both adults and children. Although most of

the novel therapies have been studied primarily in the adult rheumatic

population, many are being evaluated in children in randomized

controlled and open label trials as well. Long-term results are being

collected regarding these newer regimens in both adults and children.

Summary: This review looks at the risks and benefits of the variety of

novel therapies including the new biologics, immunosuppressives, and

stem cell transplantation currently being used in rheumatic conditions.

Using these new therapies along with traditional antirheumatic

medications, pediatric rheumatologists intervene to control disease

early and more effectively to prevent long-term damage and complications.

Chira, ; Sandborg, Christy I.

Department of Pediatrics, Division of Rheumatology, Stanford University

School of Medicine, Stanford, California, USA

Correspondence to Christy I. Sandborg, MD, Department of Pediatrics,

Division of Rheumatology, 300 Pasteur Drive, Suite G310, Stanford, CA

94305-5208, USA

Tel: 650-723-8295; e-mail: sandborg@...